Sign In
Buy HCWB
$3.20
+0.0500 (+1.59%)
At Close: Jul 31, 2026
Lead product candidate will be advanced to late IND-enabling studies to prepare for clinical trials for evaluation in the treatment of solid tumors
HCW Biologics' Shares Surge After Unveiling Next-Gen Cancer Immunotherapy Platform
09:53am, Monday, 25'th Aug 2025
HCW Biologics Inc. HCWB stock is trading higher on Monday, with a session volume of 10.85 million compared to the average volume of 132.51K as per data from Benzinga Pro.
Company's pembrolizumab-based immune checkpoint inhibitor exhibited success against solid tumors in IND-enabling studies by simultaneously activating immune cells and promoting their infiltration in
HCW Biologics Reports Second Quarter 2025 Business Highlights and Financial Results
02:44pm, Monday, 18'th Aug 2025
MIRAMAR, Fla., Aug. 18, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and dev
Tetra-functional T-cell engagers activate T cells and simultaneously reduce immunosuppression, with potent and antigen-specific anti-pancreatic cancer activities at dose levels that are well tolerated
HCW Biologics Regains Compliance with Nasdaq Capital Market Requirements
07:55am, Thursday, 26'th Jun 2025
MIRAMAR, Fla., June 26, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCWB” or the “Company”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and d
HCW Biologics Completes Deliverable and Solidifies License Agreement with WY Biotech
08:20am, Wednesday, 04'th Jun 2025
HCW Biologics earned upfront payment and will recognize revenue of $7.0 million in Q2 2025 HCW Biologics earned upfront payment and will recognize revenue of $7.0 million in Q2 2025
HCW Biologics Reports First Quarter 2025 Business Highlights and Financial Results
06:14pm, Thursday, 15'th May 2025
MIRAMAR, Fla., May 15, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and deve
HCW Biologics Announces Pricing of $5.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules
08:01pm, Tuesday, 13'th May 2025
MIRAMAR, Fla., May 13, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”), (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunothe
HCW Biologics Announces Positive Results of Studies of Proprietary Compound, HCW9206 and Availability for Commercialization
08:30am, Tuesday, 13'th May 2025
Addresses key challenges for CAR-T therapies Potential to significantly reduce costs and improve clinical efficacy of engineered effector T cells Data Shared at 2025 Annual Meeting of American Associa
HCW Biologics Announces 1-for-40 Reverse Stock Split
04:35pm, Tuesday, 01'st Apr 2025
MIRAMAR, Fla., April 01, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and de
HCW Biologics Reports Fourth Quarter and Fiscal Year 2024 Business Highlights and Financial Results
03:30pm, Friday, 28'th Mar 2025
MIRAMAR, Fla., March 28, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and de
HCW Biologics Granted Extension by the Nasdaq Hearings Panel to Regain Compliance with Continued Listing Requirements
06:55am, Thursday, 06'th Mar 2025
MIRAMAR, Fla., March 06, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (Nasdaq: HCWB), a clinical-stage biopharmaceutical company focused on discovering and de
MIRAMAR, Fla., Feb. 03, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCWB” or the “Company”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and d
MIRAMAR, Fla., Jan. 15, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCWB” or “HCW Biologics”), (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering an
